Wide Ranks

JANX

Janux Therapeutics, Inc.

46.39

Top Statistics
Market Cap 2 B Forward PE -22.88 Revenue Growth -82.60 %
Current Ratio 38.80 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -21.46 Enterprise / Revenue 137.94 Price To Sales Trailing12 Months 186.58
Profitability
Profit Margins 0.00 % Operating Margins -8164.46 %
Balance Sheet
Total Cash 658 M Total Cash Per Share 12.54 Total Debt 23 M
Total Debt To Equity 3.57 Current Ratio 38.80 Book Value Per Share 12.54
All Measures
Short Ratio 605.00 % Message Board Id finmb_676965261 Shares Short Prior Month 4 M
Return On Equity -0.1205 City San Diego Uuid 3a638123-d3da-3133-96c7-e6e8cabf84b3
Previous Close 48.00 First Trade Date Epoch Utc 1 B Book Value 12.54
Beta 3.52 Total Debt 23 M Volume 645898
Price To Book 3.70 Fifty Two Week Low 7.79 Total Cash Per Share 12.54
Total Revenue 13 M Shares Short Previous Month Date 1 B Target Median Price 69.50
Max Age 86400 Recommendation Mean 1.23 Sand P52 Week Change 0.3133
Operating Margins -8164.46 % Target Mean Price 67.25 Net Income To Common -60536000
Short Percent Of Float 0.1567 Implied Shares Outstanding 52 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 655240 Average Volume10days 655240
Total Cash 658 M Next Fiscal Year End 1 B Revenue Per Share 0.2550
Held Percent Insiders 0.0775 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 48.00 Target Low Price 25.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 49.98 Open 48.10
Free Cashflow -21559250 State CA Dividend Yield 0.00 %
Return On Assets -0.0993 Time Zone Short Name EST Trailing Eps -1.17
Day Low 46.30 Address1 10955 Vista Sorrento Parkway Shares Outstanding 52 M
Price Hint 2 Target High Price 100.00 Website https://www.januxrx.com
52 Week Change 4.31 Average Volume 643943 Forward Eps -1.60
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Quick Ratio 3857.70 %
Is_sp_500 False Regular Market Day High 49.69 Profit Margins 0.00 %
Debt To Equity 3.57 Fifty Two Week High 65.60 Day High 49.69
Shares Short 4 M Regular Market Open 48.10 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 137.94 Revenue Growth -82.60 %
Shares Percent Shares Out 0.0798 Operating Cashflow -36990000 Currency USD
Time Zone Full Name America/New_York Market Cap 2 B Is_nasdaq_100 False
Zip 92130 Quote Type EQUITY Industry Biotechnology
Long Name Janux Therapeutics, Inc. Regular Market Day Low 46.30 Held Percent Institutions 0.9458
Current Price 46.39 Address2 Suite 200 Enterprise To Ebitda -21.46
Financial Currency USD Current Ratio 38.80 Industry Disp Biotechnology
Number Of Analyst Opinions 12 Country United States Float Shares 38 M
Two Hundred Day Average 44.49 Enterprise Value 1 B Price To Sales Trailing12 Months 186.58
Forward PE -22.88 Regular Market Volume 645898 Ebitda -83883000
Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer.

The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Its development pipeline also consists of discovery stage products.

The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp.

to develop TRACTr product candidates.

Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.